^
Association details:
| Biomarker: | miR-34a underexpression |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Plasma-Based microRNA Expression Analysis in Advanced Stage NSCLC Patients Treated with Nivolumab
Published date:
09/28/2022
Excerpt:
We analyzed the expression levels and examined the clinical significance of immunoregulatory miRNAs...in patients with advanced NSCLC (N = 69) treated with anti-PD-1 (Nivolumab) immunotherapy as 2nd or 3rd line of treatment therapy....Expression of miR-34a, miR-146a, mir-200c, and miR-223 was found to be associated with response to immunotherapy....Low miR-34a expression independently predicted for shorter OS (HR: 3.189, 95% CI: 1.193-8.527; p = 0.021) in the non-SqCC subgroup.
DOI:
https://doi.org/10.3390/cancers14194739
